| Mrs Judith Althea Bock, CRNA | |
|
1 Jarrett White Rd, Tripler Amc, HI 96859-5001 | |
| (808) 433-5074 | |
| Not Available |
| Full Name | Mrs Judith Althea Bock |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 28 Years |
| Location | 1 Jarrett White Rd, Tripler Amc, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013994656 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 2522 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Endo Sedation Llc | 4789845363 | 293 |
News Archive
Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France's leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen's lab will also be a demonstration site for researchers investigating Fluidigm's technology.
Prominent health leaders representing the public, private and nonprofit sectors will speak next month at the 2012 Keeneland Conference, sponsored by the National Coordinating Center for Public Health Services and Systems Research which is housed at the University of Kentucky College of Public Health and funded by the Robert Wood Johnson Foundation.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
› Verified 4 days ago
| Entity Name | Seema A Dar Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942390901 PECOS PAC ID: 7315998937 Enrollment ID: O20050201000635 |
News Archive
Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France's leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen's lab will also be a demonstration site for researchers investigating Fluidigm's technology.
Prominent health leaders representing the public, private and nonprofit sectors will speak next month at the 2012 Keeneland Conference, sponsored by the National Coordinating Center for Public Health Services and Systems Research which is housed at the University of Kentucky College of Public Health and funded by the Robert Wood Johnson Foundation.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
› Verified 4 days ago
| Entity Name | Texas Institute Of Gastroenterology Associates , Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538267067 PECOS PAC ID: 7012927056 Enrollment ID: O20060504000434 |
News Archive
Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France's leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen's lab will also be a demonstration site for researchers investigating Fluidigm's technology.
Prominent health leaders representing the public, private and nonprofit sectors will speak next month at the 2012 Keeneland Conference, sponsored by the National Coordinating Center for Public Health Services and Systems Research which is housed at the University of Kentucky College of Public Health and funded by the Robert Wood Johnson Foundation.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
› Verified 4 days ago
| Entity Name | Joycelyn M. Theard M.d,p.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346424231 PECOS PAC ID: 7214015817 Enrollment ID: O20080630000289 |
News Archive
Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France's leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen's lab will also be a demonstration site for researchers investigating Fluidigm's technology.
Prominent health leaders representing the public, private and nonprofit sectors will speak next month at the 2012 Keeneland Conference, sponsored by the National Coordinating Center for Public Health Services and Systems Research which is housed at the University of Kentucky College of Public Health and funded by the Robert Wood Johnson Foundation.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
› Verified 4 days ago
| Entity Name | Endo Sedation Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588931174 PECOS PAC ID: 4789845363 Enrollment ID: O20120406000221 |
News Archive
Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France's leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen's lab will also be a demonstration site for researchers investigating Fluidigm's technology.
Prominent health leaders representing the public, private and nonprofit sectors will speak next month at the 2012 Keeneland Conference, sponsored by the National Coordinating Center for Public Health Services and Systems Research which is housed at the University of Kentucky College of Public Health and funded by the Robert Wood Johnson Foundation.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Judith Althea Bock, CRNA 1265 Hudson Cir, Honolulu, HI 96819-1150 Ph: (808) 294-8077 | Mrs Judith Althea Bock, CRNA 1 Jarrett White Rd, Tripler Amc, HI 96859-5001 Ph: (808) 433-5074 |
News Archive
Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France's leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen's lab will also be a demonstration site for researchers investigating Fluidigm's technology.
Prominent health leaders representing the public, private and nonprofit sectors will speak next month at the 2012 Keeneland Conference, sponsored by the National Coordinating Center for Public Health Services and Systems Research which is housed at the University of Kentucky College of Public Health and funded by the Robert Wood Johnson Foundation.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
› Verified 4 days ago
Mr. Brian Eric Lauer, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Jarrett White Rd, Tripler Army Medical Center Attn: Mchk-qs, Tripler Amc, HI 96859 Phone: 808-433-2460 | |
Dr. Reagan Drebenstedt, DNP Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1 Jarrett White Rd, Tripler Amc, HI 96859 Phone: 231-675-0874 | |
Stephen Charles Wuertz, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Jarrett White Rd, Tripler Army Medical Center, Tripler Amc, HI 96859 Phone: 808-433-2460 Fax: 808-433-1558 | |
Cristal Lagail Trotter, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1 Jarrett White Rd, Tripler Amc, HI 96859 Phone: 877-998-9011 | |
Elizabeth O Kelly, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1 Jarrett White Rd, Tripler Army Medical Center Attn Mchk-qs, Tripler Amc, HI 96859 Phone: 808-433-2460 | |
Mr. Christopher Len Deese, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Jarrett White Rd, Tripler Army Medical Center, Tripler Amc, HI 96859 Phone: 808-433-2460 Fax: 808-433-1558 |